NewsSOS
Moderna (MRNA) shares closed at $236.50 on October 15, 2026, marking their highest level in a year. The stock has gained 282.6% over the past three months, significantly outpacing the 4.1% return of the S&P 500.
This surge follows a major catalyst on August 19, when Moderna and Merck announced that their personalized cancer treatment, intismeran, achieved its targets in a Phase 3 melanoma trial.
On that day, Moderna shares nearly tripled. Detailed results for the treatment are scheduled for release at a medical meeting on October 24.
The drug is not yet approved, and Moderna would share profits equally with Merck. At current price levels, the company trades at a significant premium relative to the broader market.
Keep reading